The concomitant consumption of cod liver oil causes a reduction in the daily Diclofenac Sodium usage in rheumatoid arthritis patients: A pilot study

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 7, 2013, Pages 1347-1351

  Kumar Gupta, Vinay ^a   Khan Zafer, Z Y ^a   Ahmad, Mushtaq ^a  

^a GANDHI MEDICAL COLLEGE   (India)

Author keywords

Diclofenac sodium; Essential fatty acid; Rheumatoid arthritis; Visual analogue scale

Indexed keywords

COD LIVER OIL; DICLOFENAC; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; RETINOL; VITAMIN D;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DOSE RESPONSE; DRUG CAPSULE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK REDUCTION; SCORING SYSTEM; SINGLE DRUG DOSE; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 84879914162     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/6266.3126     Document Type: Article

References (25)

1. Longo L Dan, Kasper L Dennis, Jameson Larry J, Fauci S Anthony, Hauser L Stephen, Loscalzo Joseph. Rheumatoid Arthritis.Harrison's. Principles of Internal Medicine. 18ed. 2012; 321: 4356-70.
2. Milind Parle, Sushila Kaura. How to live with Rheumatoid Arthritis? IRJP. 2012; 3 (3): 115-21.
3. Simopoulos P Artemis. Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases. Journal of the American College of Nutrition. 2002; 21 (6): 495-505.
4. Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acid. Nutr Rev. 2010; 68 (5): 280-89.
5. Belch JJ, Hill A. Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr. 2000; 71 (Suppl): 352S-6S.
6. Shearer GC, Harris WS, Pedersen TL, Newman JW. Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J Lipid Res. 2010; 51:2074-81.
7. Oh Young Da, Talukdar Saswata, Bae Ju Eun, Imamura Takeshi, Morinaga Hidetaka, Fan Qiang Wu, et al. GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects. Cell. 2010; 142: 687-98.
8. Madhyastha S, Bairy KL, Somayaji SN. Protective Effect of Vitamin A on Methotrexate Induced Micronuclei. IJPT. 2007; 6:1-4.
9. Merlino A Linda, Curtis Jeffrey, Mikuls R Ted, Cerhan R James, Criswell A. Lindsey, Saag G. Kenneth. Vitamin D Intake Is Inversely Associated With Rheumatoid Arthritis. Arthritis & Rheumatism. 2004; 50 (1):72-77.
10. Aletaha D, Neogi T, Silman A J, Funovits J. 2010 Rheumatoid Arthritis Classification Criteria, An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism. 2010; 62 (9): 2569-81.
11. Hochberg C Marc, Chang W Rowland, Dwosh Isaac, Lindsey Stephen, Pincus Theodore, Wolfe Frederick. ACR 1991 Revised Criteria for the classification of Global Functional Status in Rheumatoid Arthritis. Arthritis and Rheumatism. 1992; 35 (5): 498-502.
12. Chou R, Helfand M, Peterson K, Dana T, Roberts C. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis 2006; AHRQ Publication No. 06-EHC009-EF: APPENDIX C.
13. Sokka T. Assessment of pain in rheumatic diseases. Clin Exp Rheumatol. 2005; 23 (Suppl. 39): S77-S84.
14. Gould D, Kelly D, Goldstone L, Gammon J. Examining the validity of pressure ulcer risk assessment scales: developing and using illustrated patient simulations to collect the data. J Clin Nurs. 2001 Sep; 10(5): 697-706.
15. Tripathi KD. Nonsteroidal Antiinflammatory Drugs and Antipyretic-Analgesics. Essentials of Medical Pharmacology-6th ed. 2008; 14: 184-201.
16. Ariza-Ariza R, Mestanza-Peralta M, Cardiel MH. Omega-3 fatty acids in rheumatoid arthritis: an overview. Semin Arthritis Rheum.1998; 27: 366-70.
17. Galarraga B, Ho M, Youssef MH, Hill A, McMahon H, Hall C, et al. Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology. 2008; 47: 665-69.
18. Harris S William, Kris-Etherton M Penny, Harris A. Kristina. Intakes of Long-Chain Omega-3 Fatty Acid Associated with Reduced Risk for Death from Coronary Heart Disease in Healthy Adults. Current Atherosclerosis Reports. 2008, 10: 503-09.
19. Lee H John, O'Keefe H James, Lavie J Carl, Marchioli Roberto, Harris S William. Omega-3 Fatty Acids for Cardioprotection. Mayo Clin Proc. 2008; 83 (3): 324-32.
20. Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). EFSA Journal. 2012; 10 (7): 2815.
21. Duda K Monika, O'Shea M Karen, Stanley C William. n-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovascular Research. 2009; 84, 33-41.
22. Broder R Anna, Tobin N Jonathan, Putterman Chaim. Disease-specific definitions of vitamin D deficiency need to be established in autoimmune and non-autoimmune chronic diseases: a retrospective comparison of three chronic diseases. Arthritis Research & Therapy. 2010; 12: R191.
23. Lewis J Christine. Letter Regarding Dietary Supplement Health Claim for Omega-3 Fatty Acids and Coronary Heart Disease. 2000. Docket No.91N-0103. http://vm.cfsan.fda.gov/~dms/ds-ltr11.html
24. National Academy of Sciences. Dietary Reference Intakes (DRIs): Tolerable Upper Intake Levels (UL), Vitamins 2004.
25. Ross Catharine A, Manson E Joann, Abrams A Steven, Aloia F John, Brannon M Patsy, Clinton K Steven, et al. The 2011 report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine. J Clin Endocrinol Metab. 2011; 96 (1): 53-58.